We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Eye Care

Journal Scan / Research · April 11, 2017

Risk for Low Visual Acuity in Neovascular AMD After 1 or 2 Years of Anti-VEGF Treatment

Retina (Philadelphia, Pa.)

 

Additional Info

Disclosure statements are available on the authors' profiles:

Retina (Philadelphia, Pa.)
Risk for Low Visual Acuity After 1 and 2 Years of Treatment With Ranibizumab or Bevacizumab for Patients With Neovascular Age-Related Macular Degeneration
Retina (Philadelphia, Pa.) 2017 Jan 30;[EPub Ahead of Print], I Westborg, S Albrecht, A Rosso

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading